Eton Pharmaceuticals (ETON) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Xeris Biopharma (XERS) over the past year, gaining 161.6% versus a gain of 24.3%. Over five years, ETON leads with a +950.9% price change compared with +409.5% for XERS. Xeris Biopharma is the larger company by market cap ($1.86 billion vs $1.56 billion), about 1.2 times the size, while Eton Pharmaceuticals is growing revenue faster (+104.9% vs +43.7%).
On valuation, Eton Pharmaceuticals trades at a lower forward P/E (21.2x vs 27.5x for Xeris Biopharma). Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -5.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | XERS |
|---|---|---|
| Share price | $54.75 | $10.19 |
| Market cap | $1.56B | $1.86B |
| 1-day change | -0.24% | +0.79% |
| YTD return | +223.77% | +29.81% |
| 1-year return | +161.59% | +24.27% |
| 5-year return | +950.86% | +409.50% |
| P/E ratio (TTM) | 136.88 | — |
| Forward P/E | 21.22 | 27.54 |
| EPS (TTM) | $0.40 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $79.95M | $291.85M |
| Revenue growth (YoY) | +104.94% | +43.72% |
| Net income (latest FY) | $-4.60M | $554.00K |
| Gross margin | 53.46% | 85.41% |
| Operating margin | -1.06% | 8.53% |
| Net margin | -5.75% | 0.19% |
| 52-week high | $66.37 | $11.33 |
| 52-week low | $14.27 | $5.25 |
| Distance from 52-week high | -17.51% | -10.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.68% | +26.20% |
| Average volume | 609.36K | 2.17M |
| Shares outstanding | 28.58M | 182.32M |
| Employees | 44 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed XERS by 137.3 percentage points over the past year.
- Xeris Biopharma is more profitable, keeping 0.2 cents of every revenue dollar as net income versus -5.8 cents for Eton Pharmaceuticals.
- Eton Pharmaceuticals grew revenue faster in its latest fiscal year (+104.94% vs +43.72%).
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
ETON vs XERS FAQ
Which is bigger, Eton Pharmaceuticals or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.86B compared with $1.56B for Eton Pharmaceuticals (ETON).
Which stock has performed better over the past year, ETON or XERS?
ETON returned +161.59% over the past 12 months, compared with +24.27% for XERS (price return, excluding dividends). Past performance does not predict future results.
Are Eton Pharmaceuticals and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.